Klinische Monatsblätter für Augenheilkunde, Table of Contents Klin Monbl Augenheilkd 2024; 241(10): 1117-1118DOI: 10.1055/a-2340-8299 Editorial From Trial to Trial: Diminishing Effects Sizes of Interventions for Myopia Control – a Call for Critical Reassessment Wolf Lagrèze Recommend Article Abstract Buy Article Full Text References References 1 Dolgin E. The myopia boom. Nature 2015; 519: 276-278 2 Chia A, Chua WH, Cheung YB. et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5 %, 0.1 %, and 0.01 % doses (Atropine for the Treatment of Myopia 2). Ophthalmology 2012; 119: 347-354 3 Schuster AK, Elflein HM, Pokora R. et al. [Prevalence and Risk Factors of Myopia in Children and Adolescents in Germany – Results of the KiGGS Survey]. Klin Padiatr 2017; 229: 234-240 4 Schuster AK, Krause L, Kuchenbäcker C. et al. Prevalence and Time Trends in Myopia Among Children and Adolescents. Dtsch Arzteblatt Int 2020; 117: 855-860 5 Wesemann W. [Analysis of spectacle lens prescriptions shows no increase of myopia in Germany from 2000 to 2015]. Ophthalmologe 2018; 115: 409-417 6 Williams KM, Verhoeven VJM, Cumberland P. et al. Prevalence of refractive error in Europe: the European Eye Epidemiology (E(3)) Consortium. Eur J Epidemiol 2015; 30: 305-315 7 Tideman JWL, Snabel MCC, Tedja MS. et al. Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. JAMA Ophthalmol 2016; 134: 1355-1363 8 Loughman J, Kobia-Acquah E, Lingham G. et al. Myopia outcome study of atropine in children: Two-year result of daily 0.01 % atropine in a European population. Acta Ophthalmol 2024; 102: e245-e256 9 Zadnik K, Schulman E, Flitcroft I. et al. Efficacy and Safety of 0.01 % and 0.02 % Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol 2023; 141: 990-999
